Top Biotechnology Startups in 2026

Safetraces, Inc. lets you trace food from fork-to-farm - quickly and safely.

The human microbiome is the next frontier of precision medicine. Just like our genes, our microbiome is unique and can help predict our health in many ways, from our disease risk to how the drugs we take effect us. Most importantly, unlike our genes, it's dynamic - so can be harnessed for better health. There's just one problem - that same dynamism makes it extremely challenging to study, and that slows progress. Microbiome researchers need more data to turn potential into reality. That's why we're creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions. The outcome? Microbiome-based prescriptions and solutions that are personalized to meet patient needs.

Ambry Genetics Corporation is a genetic testing laboratory that provides clinical diagnostics testing services for genetic conditions. We have a highly adaptable, ever changing work environment. You’ll notice right away our employees are passionate about their work and the clock is not their priority. We offer high quality testing and solutions; our services are client-tailored. We have an exceptional atmosphere here and our culture is unbeatable!

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. - The BioScience segment manufactures recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products and technologies used in adult stem-cell therapies; and vaccines. - The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs, intravenous nutrition products; infusion pumps; and inhalation anesthetics. This segment also offers products and services related to pharmacy compounding, drug formulation, and packaging technologies. - The Renal segment provides products to treat end-stage renal disease and irreversible kidney failure. This segment also offers solutions and other products for peritoneal dialysis, a home-based therapy and product for hemodialysis, which is conducted in a hospital or clinic. Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 6,500 employees and serves more than 85,000 research and industry customers worldwide through its global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more.

BioLM is building the API layer for biological language models - making it easy to program DNA and proteins like software. We provide inference, tokenization, and fine-tuning APIs purpose-built for biological sequences, enabling researchers and developers to generate, analyze, and optimize DNA and amino acid sequences at scale. On top of our APIs, we’re building scientific interfaces that make these models usable in real workflows - from sequence design to iterative experimentation. Our goal is to make modern AI-native biology accessible to anyone building in biotech.